Press release
Cancer Biomarkers Market to Reach USD 74.3 Billion by 2035, Driven by Liquid Biopsies, AI Profiling, and Multi-Cancer Early Detection
Cancer Biomarkers Market to Reach USD 74.3 Billion by 2035, Driven by Liquid Biopsies, AI Profiling, and Multi-Cancer Early Detect
This rapid expansion is being driven by advances in protein and genomic biomarker assays, liquid biopsy platforms (ctDNA), and AI-driven multi-omic profiling that enable earlier detection, real-time monitoring, and precision therapy selection.
MarketGenics positions cancer biomarkers as a strategic pillar of modern oncology-accelerating screening programs, enabling targeted therapeutics, and improving longitudinal disease management in an era of rising incidence and expanding precision-medicine adoption.
Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Cancer Biomarkers Market Research Report: https://marketgenics.co/press-releases/cancer-biomarkers-market-00931
Recent Developments Shaping the Market
Abbott launches AI-powered Alinity Cancer Biomarker Panel (Apr 2025)
Abbott unveiled an integrated Alinity panel for early detection, combining protein and molecular markers with AI risk scoring and cloud-enabled provider workflows for near-real-time clinical action.
Roche debuts AVENZIA Precision Oncology Suite (Jun 2025)
Roche introduced AVENZIA, an AI-driven profiling and treatment-matching platform that links liquid biopsy data to real-time therapeutic recommendations across targeted and immuno-oncology regimens.
Liquid biopsy & multi-omic rollouts
Multiple diagnostic vendors are scaling ctDNA and multi-marker blood tests to support screening and minimal-residual-disease (MRD) monitoring-moving detection earlier and enabling longitudinal therapy guidance.
Cancer Biomarkers Market Forecast 2035
The market is set to create an incremental opportunity of USD 47.4 billion between 2025 and 2035.
North America will remain the largest and most advanced market due to deep clinical adoption, payer coverage for companion diagnostics, and concentrated R&D activity.
Asia-Pacific will deliver the fastest growth as diagnostic capacity expands, public screening programs broaden, and private lab networks scale.
Europe will grow steadily, propelled by strong oncology pipelines, national screening initiatives, and reimbursement for validated biomarker tests.
By 2035, biomarker-driven workflows will be embedded across screening, treatment selection, and post-treatment surveillance-shifting oncology care toward earlier, more personalized interventions.
To know more about the Cancer Biomarkers Market - Download our Sample Report: https://marketgenics.co/download-report-sample/cancer-biomarkers-market-00931
Key Drivers, Challenges, and Opportunities
Driver - Early detection and treatment matching via liquid biopsy and genomic profiling
Non-invasive blood tests (ctDNA, protein panels) and comprehensive genomic profiling are enabling earlier diagnosis and precise therapeutic selection. These reduce time-to-treatment and can identify actionable mutations for targeted drugs and immunotherapies.
Restraint - High validation costs and regulatory fragmentation
Developing clinically validated biomarkers requires large prospective studies, expensive assay validation, and complex regulatory approvals that vary by market-slowing rollout and limiting payer reimbursement in some regions.
Opportunity - Multi-Cancer Early Detection (MCED) and real-time MRD monitoring
MCED panels and MRD assays present large commercial opportunities-population screening and therapy-follow monitoring can unlock high-volume use cases beyond traditional single-tumor diagnostics. AI enrichment of multi-omic signatures further increases diagnostic yield and clinical utility.
Key Trend - AI-Enabled, Multi-Omic Biomarker Profiling
AI and machine learning are rapidly becoming essential to integrate protein, genomic, epigenetic, and metabolic signals into robust predictive models. Examples include AI risk-scoring for early detection, algorithmic treatment matching, and longitudinal MRD tracking-transforming raw assay data into actionable clinical intelligence at scale.
Buy Now: https://marketgenics.co/buy/cancer-biomarkers-market-00931
Segmental Insights
Protein Biomarkers Lead (~49% share in 2025)
Protein markers remain the largest subsegment because of broad clinical familiarity (PSA, CA-125), ease of assay, and applicability across hospital labs and screening programs.
Genetic & ctDNA Segments Accelerating
Genomic panels, ctDNA MRD assays, and epigenetic markers are the fastest-growing high-value categories-key for targeted therapy selection and liquid-biopsy screening strategies.
Applications: Screening, Companion Diagnostics & Monitoring
Screening (MCED), companion diagnostics for targeted drugs, and MRD monitoring are the primary revenue drivers going forward.
Regional Highlights
North America: Leads on clinical adoption, payer coverage for companion diagnostics, and rapid uptake of liquid biopsies.
Asia-Pacific: Fastest growth-scaling public screening and private diagnostic capacity.
Europe: Steady adoption with emphasis on health-technology assessment and reimbursement for validated biomarkers.
Middle East, Africa & Latin America: Gradual uptake driven by private labs and selective national screening pilots.
Competitive Landscape
The cancer biomarkers market is moderately consolidated, with the top five players accounting for ~44% share in 2024.
Tier-1 Leaders: Roche, Abbott, Thermo Fisher Scientific, QIAGEN, Illumina.
Specialists & Innovators: Guardant Health, Foundation Medicine, Exact Sciences, Bristol-Myers Squibb (companion diagnostics tie-ups), and a growing cohort of AI/diagnostics start-ups.
Competition centers on assay sensitivity/specificity, multi-omic integration, AI analytics, regulatory evidence generation, and payer access models.
Get a preview of our Cancer Biomarkers Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/cancer-biomarkers-market-00931
Future Outlook
By 2035, cancer biomarkers will have reshaped oncology pathways: population screening with MCED panels, routine ctDNA MRD surveillance to guide adjuvant therapy decisions, and AI-assisted matching of patients to targeted regimens and clinical trials.
Stakeholders that combine robust clinical validation, scalable assay platforms, and payer-friendly value evidence will capture the largest share of the USD 74.3 billion market.
Prominent Companies Operating in the Global Cancer Biomarkers Market
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific, QIAGEN N.V., Illumina, Guardant Health, Foundation Medicine, Exact Sciences, and other diagnostic innovators and clinical lab networks.
About Us
MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.
We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.
Contact:
Mr. Debashish Roy
MarketGenics India Pvt. Ltd.
800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States
USA: +1 (302) 303-2617
Email: sales@marketgenics.co
Website: https://marketgenics.co
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Biomarkers Market to Reach USD 74.3 Billion by 2035, Driven by Liquid Biopsies, AI Profiling, and Multi-Cancer Early Detection here
News-ID: 4205245 • Views: …
More Releases from MarketGenics India Pvt. Ltd.
Clinical Laboratory Tests Market to Reach USD 383.8 Billion by 2035, Driven by A …
The global Clinical Laboratory Tests Market is projected to grow from USD 131.5 billion in 2025 to USD 383.8 billion by 2035, expanding at a CAGR of 10.2% during the forecast period.
This rapid expansion is driven by the accelerating adoption of NGS and molecular diagnostics, AI-enabled laboratory workflows, and the growth of home-collection and point-of-care testing that broaden access and testing volumes across populations.
MarketGenics, a leading research firm, highlights…
Clinical Trial Services Market to Reach USD 135 Billion by 2035, Driven by AI, D …
The global Clinical Trial Services Market is projected to grow from USD 62.2 billion in 2025 to USD 135 billion by 2035, expanding at a CAGR of 7.3% during the forecast period. Growth is driven by rising demand for biologics and personalized medicine, expansion of decentralized and hybrid trial models, and the increasing integration of AI and digital ecosystems that streamline operations and reduce trial cycle times.
MarketGenics, a leading research…
Clinical Trial Supplies Market to Reach USD 9.7 Billion by 2035, Driven by Biolo …
The global Clinical Trial Supplies Market is projected to grow from USD 4.6 billion in 2025 to USD 9.7 billion by 2035, expanding at a CAGR of 7.8% during the forecast period. This growth is fueled by the rising complexity of biologics and cell therapies, the expansion of decentralized clinical trial models, and increasing integration of AI and digital platforms in supply chain management.
MarketGenics, a leading research firm, highlights clinical…
Cochlear Implant Market to Reach USD 7.2 Billion by 2035, Driven by Pediatric Pr …
The global Cochlear Implant Market is valued at USD 2.8 billion in 2025 and is projected to reach USD 7.2 billion by 2035, expanding at a CAGR of 8.9%. Growth is underpinned by expanding pediatric implant programs, rising age-related hearing loss, wider access in emerging markets, and continuous product innovation in signal processing, connectivity, and fully implantable systems.
MarketGenics positions cochlear implants as a rapidly maturing category within hearing care where…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
